Early stage cancer biotech Precision BioSciences sets terms for $126 million IPO

Shutterstock photo

Precision BioSciences, an early stage cancer biotech developing gene-edited Car T cell therapies, announced terms for its IPO on Monday.

The Durham, NC-based company plans to raise $126 million by offering 7.9 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Precision BioSciences would command a fully diluted market value of $881 million. 

Precision BioSciences was founded in 2006 and booked $11 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol DTIL. J.P. Morgan, Goldman Sachs, Jefferies and Barclays are the joint bookrunners on the deal. It is expected to price during the week of March 25, 2019.

The article Early stage cancer biotech Precision BioSciences sets terms for $126 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?